Collective Activation of MRI Agents via Encapsulation and Disease-Triggered Release

Citations Over TimeTop 10% of 2013 papers

Abstract

An activation mechanism based on encapsulated ultrasmall gadolinium oxide nanoparticles (Gd oxide NPs) in bioresponsive polymer capsules capable of triggered release in response to chemical markers of disease (i.e., acidic pH, H2O2) is presented. Inside the hydrophobic polymeric matrices, the Gd oxide NPs are shielded from the aqueous environment, silencing their ability to enhance water proton relaxation. Upon disassembly of the polymeric particles, activation of multiple contrast agents generates a strong positive contrast enhancement of >1 order of magnitude.

Related Papers

• → Design and synthesis of novel DOTA(Gd3+)–polymer conjugates as potential MRI contrast agents(2011)31 cited
• → Binding of a dimeric manganese porphyrin to serum albumin: towards a gadolinium-free blood-pool T 1 MRI contrast agent(2014)27 cited
• → Block Copolymer-Based Gadolinium Nanoparticles as MRI Contrast Agents with High T ₁ Relaxivity(2012)21 cited
• → A self-assembly heterotrinuclear gadolinium(III)–iron(II) complex as a MRI contrast agent(2011)13 cited
• Relaxivities of Gadolinium Heteropoly Complexes in Aqueous Solution for MRI Contrast Agent(2000)